About this item:

249 Views | 165 Downloads

Author Notes:

Reprints: Dolly Aguilera, MD, 5455 Meridian Mark Suite 400, Atlanta, GA 30342 (dolly.aguilera@choa.org).

R.F.: Speakers Bureau for Novartis for Afinitor.

T.J.M.D.: Paid consultant for Novartis (2012)

The remaining authors declare no conflict of interest.


Research Funding:

R.C.C.: Received funding from NIH R01CA172392, a Scholar Award (St. Baldrick’s Foundation), Springboard Grant (Alex’s Lemonade Stand Foundation), and Research Grants (Childhood Brain Tumor Foundation, CURE Childhood Cancer Foundation, and the Children’s Center for Neuroscience Pilot Grant).


  • Science & Technology
  • Life Sciences & Biomedicine
  • Oncology
  • Hematology
  • Pediatrics
  • everolimus
  • SEGA
  • tuberous sclerosis
  • spinal cord

Response of Subependymal Giant Cell Astrocytoma With Spinal Cord Metastasis to Everolimus


Journal Title:

Journal of Pediatric Hematology/Oncology


Volume 36, Number 7


, Pages E448-E451

Type of Work:

Article | Post-print: After Peer Review


Background: Brain subependymal giant cell astrocytomas (SEGAs) in patients with tuberous sclerosis have been reported to respond to everolimus.Methods: A 15-year-old male patient with intractable seizures and multiple SEGAs of the brain developed leptomeningeal enhancement and multiple metastatic, histologically confirmed SEGAs of the spinal cord. He received daily everolimus at a dose of 3 mg/m2 for 6 weeks, which was then increased to 6 mg/m2.Results: Magnetic resonance image of the brain and spine showed significant reduction in the size of SEGAs after 6 weeks of treatment. The patient has remained free of progression for 24 months. Additional benefits included: excellent seizure control, decrease in the size of cardiac rhabdomyomas, and improved quality of life.Conclusions: We describe a rare case of metastatic SEGA, which was successfully treated with everolimus.

Copyright information:

© 2013 by Lippincott Williams & Wilkins.

Export to EndNote